Options to control asthma by means of a newly developed FeNO device for use at home

Bosch Healthcare Solutions GmbH0 个研究点目标入组 87 人开始时间: 2022年7月1日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

•Patients of either gender aged 18-75 years (inclusive)
•- Written informed consent
•- Diagnosis of asthma in the opinion of the investigator (see rational) for at least 6 months prior to visit 1
•- Patients capable to use a smart phone and a digital device
•- Patients owning a smartphone and willing to use it for trial purposes (installing and using the device related free-of-charge App, sending recorded data to PI via E-mail).

•- Treatment with systemic corticosteroids and/or hospitalization for asthma exacerbation within the past 14 days prior to visit 1
•- Significant, non-reversible, active pulmonary disease (e.g., COPD, cystic fibrosis, bronchiectasis, tuberculosis)
•- Subjects suffering from acute upper or lower respiratory infection including common cold, influenza, or pneumonia.
•- Current smokers
•- Severe acute concomitant diseases during the previous 14 days prior to visit 1
•- Active SARS-CoV-2 infection confirmed by positive PCR test within the past 4 weeks prior to V1
•- Simultaneous participation in an investigational clinical trial
•- Family relationship with operators or study personnel.

发起方